14473 Potsdam, de
+49 (331) 5818478-5
GILUPI Strengthens Executive Team - Appoints Dr. Jens Pfannkuche as General Manager
Previously, Dr. Pfannkuche worked in research and development, regulatory affairs, clinical studies, business development and licensing in the medical device industry including B.R.A.H.M.S - part of Thermo Fisher Scientific. Most recently, he served in various functions at B.R.A.H.M.S - part of Thermo Fisher Scientific and as Vice President Clinical Business Development and Regulatory Affairs at BRUKER Daltonik GmbH, where he carried global responsibility for the IVD product line regarding the clinical business development and licensing and the regulatory market access. Dr. Pfannkuche also led the MALDI mass spectrometry Imaging business entering the clinical pathology market. Dr. Pfannkuche studied Biology at the University of North West Wales /UK and University of Otago / NZ and did his doctoral thesis in vibrational spectroscopy at the Polish Academy of Science. He has more than 15 years of experience in the field of implantable medical devices and in vitro diagnostic products in ophthalmology, oncology, infectiology and cardiovascular indications, and has been active in global clinical development and business-to-business licensing and deal-making projects with global medical device and IVD companies.
“I am proud to be part of GILUPI and to enable leveraging GILUPIs potential in liquid biopsy technology for the clinical, industrial and research markets”, says Jens Pfannkuche. “In light of my experience and network in the diagnostic industry regarding break-through technology, I foresee that GILUPI will play a major role in the growing circulating tumor cell market to serve patients with less invasive, cost effective diagnostic solutions in the near future. I would like to thank the shareholders for their trust and I am looking forward to fully utilize the commercial potential of GILUPI in this attractive and growing market“.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.